Q-omics provides the consensus-scored CTRC profile across patient tissues and cancer cell-line models. CTRC expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CTRC is differentially expressed in 8, with the highest sampling consensus in CHOL. Additionally, CTRC RNA expression shows 14,680 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, CHOL, and THYM as cancer lineages where CTRC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTRC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTRC survival associations across molecular data types. CTRC RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTRC RNA expression–survival associations across cancer types. High CTRC expression shows unfavorable associations in KIRC, ACC, UVM, LGG, OV and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CTRC RNA expression.
This table summarizes CTRC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in CHOL for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CTRC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTRC shows lower tumor expression in KICH and BLCA and higher tumor expression in CHOL, THCA, READ and COAD. The CHOL box plot shows higher CTRC RNA expression in tumor versus normal tissue (log2 FC = +0.140, t-test p < 0.001).
This table shows molecular features associated with CTRC in patient tissues and cancer cell lines. In patient samples, CTRC shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CTRC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_SCLC.
